BioVaxys Technology (BioVaxys Technology) Construction In Progress : $0.00 Mil (As of Jul. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Construction In Progress?

BioVaxys Technology Construction In Progress Historical Data

The historical data trend for BioVaxys Technology's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Construction In Progress Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Construction In Progress

BioVaxys Technology Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
Construction In Progress	Get a 7-Day Free Trial															-	-	-	-	-

BioVaxys Technology Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

BioVaxys Technology (BioVaxys Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.